| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Compassionate Oncology Medical Group, Los Angeles, California, USA
Correspondence: Robert L. Leibowitz, M.D., Compassionate Oncology Medical Group, 2080 Century Park East, #601, Los Angeles, California 90067, USA. Telephone: 310-229-3555; Fax: 310-229-3554; e-mail: help{at}drsteventucker.com
Objectives. To determine the effectiveness of triple androgen blockade as an alternative to watchful waiting, radical prostatectomy or radiation therapy in the management of patients with clinical stage T1 to T3 prostate cancer.
Methods. The records of 110 consecutive patients were retrospectively evaluated. Patients were treated with a three-drug androgen blockade regimen, consisting of a luteinizing hormone-releasing hormone agonist (leuprolide or goserelin) plus an antiandrogen (flutamide or bicalutamide) plus finasteride (a 5-alpha-reductase inhibitor), followed by finasteride maintenance therapy, as the sole intervention. All patients refused local therapy and had their prostates intact. Determinants of efficacy included serum prostate-specific antigen (PSA) levels and disease-specific survival.
Results. Patients were treated for a median of 13 months with triple androgen blockade. At baseline, mean PSA level was 13.2 ± 1.2 ng/ml (range, 0.39-100 ng/ml), and mean Gleason score was 6.6 ± 0.1 (range, 4-10). During treatment, PSA levels declined to
Conclusions. Although median follow-up is short, triple androgen blockade therapy followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized or locally advanced prostate cancer. Further study of this approach is warranted.
0.1 ng/ml in all patients, with a median time of 3 months. After a median follow-up of 36 months since initiation of treatment, PSA levels have remained stable in 105 of 110 patients (95.5%). At a median follow-up of 55 months (range, 38-125 months), the mean PSA level for the first 57 patients treated in this series is 1.88 ± 0.1 (range, 0-11.0 ng/ml). Only 9 of 110 (8.1%) patients have a PSA level 
4.0 ng/ml. To date, no patient has received a second cycle of hormone blockade.
This article has been cited by other articles:
 |
|
 |
|
  M. A. Uhlman, J. W. Moul, P. Tang, D. A. Stackhouse, and L. Sun Review: Risk stratification in the hormonal treatment of patients with prostate cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 79 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 M. TARLE, B. SPAJIC, I. KRALJIC, and Z. KUSIC Continuous Finasteride Therapy for Benign Prostate Hypertrophy Upgrades Both Neuroendorcine Differentiation and Aggressive Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1797 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishiyama, Y. Hashimoto, and K. Takahashi The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7121 - 7126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Hellerstedt and K. J. Pienta The Current State of Hormonal Therapy for Prostate Cancer CA Cancer J Clin, May 1, 2002; 52(3): 154 - 179. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
